Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 4/20 | 1.00 |
| ▸ | GSK3B | P49841 | 4/20 | 1.00 |
| ▸ | CMA1 | P23946 | 1/20 | 0.72 |
| ▸ | MGLL | Q99685 | 5/20 | 0.69 |
| ▸ | FAAH | O00519 | 2/20 | 0.69 |
| ▸ | CASP3 | P42574 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL146412 | 0.83 | MGLL (1.00) | GSK3AGSK3BCMA1MGLLFAAH | |
| SCHEMBL20804282 | 0.83 | GSK3A (0.69) | GSK3AGSK3BCMA1MGLLFAAH | |
| SCHEMBL3381344 | 0.81 | GSK3A (1.00) | GSK3AGSK3BCMA1MGLLMEN1 | |
| SCHEMBL21348197 | 0.81 | GSK3A (0.68) | GSK3AGSK3BCMA1MGLLFAAH | |
| SCHEMBL17123192 | 0.81 | GSK3A (0.66) | GSK3AGSK3BCMA1MGLLFAAH | |
| SCHEMBL8331785 | 0.79 | CMA1 (0.70) | GSK3AGSK3BCMA1CASP3MEN1 | |
| SCHEMBL2643216 | 0.79 | CMA1 (0.70) | GSK3AGSK3BCMA1CASP3MEN1 | |
| SCHEMBL41389 | 0.79 | CMA1 (0.70) | GSK3AGSK3BCMA1CASP3MEN1 | |
| SCHEMBL7226680 | 0.79 | CMA1 (0.76) | GSK3AGSK3BCMA1MGLLFAAH | |
| SCHEMBL9113591 | 0.78 | MGLL (0.64) | GSK3AGSK3BCMA1MGLLFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4678641-A1 | QUINOLINONE COMPOUND AND NAPHTHYRIDINONE COMPOUND AND USE THEREOF | Shanghai Helioson Pharmaceutical Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| US-20250214971-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2025-07-03 | — | — | US | disclosed |
| CN-120152713-A | Tricyclic aryl derivatives and compositions and methods thereof | 昂胜医疗科技公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-116113627-B | Ji Yin-dole glucocorticoid receptor antagonists | 科赛普特治疗公司 | 2025-06-03 | — | — | CN | disclosed |
| US-12180186-B2 | Quaternary indazole glucocorticoid receptor antagonists | CORCEPT THERAPEUTICS INCORPORATED (US) | 2024-12-31 | — | — | US | disclosed |
| EP-4472968-A1 | INHIBITORS OF RAF KINASES | PIERRE FABRE MEDICAMENT (FR) | 2024-12-11 | — | — | EP | disclosed |
| CN-118974036-A | Inhibitors of RAF kinase | 皮埃尔法布雷医药公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118574834-A | Fused tetracyclic compounds, compositions and uses thereof | 泰博生物科技股份有限公司 | 2024-08-30 | — | — | CN | disclosed |
| WO-2024149378-A1 | QUINOLINONE COMPOUND AND NAPHTHYRIDINONE COMPOUND AND USE THEREOF | 上海超阳药业有限公司 | 2024-07-18 | — | — | WO | disclosed |
| US-20240182467-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2024-06-06 | — | — | US | disclosed |
| US-6872737-B2 | Heterocyclic inhibitors of glycogen synthase kinase GSK-3 | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2005-03-29 | — | — | US | disclosed |
| US-20050014803-A1 | Enzyme inhibitors | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, A SPAIN CORPORATION | 2005-01-20 | — | — | US | disclosed |
| EP-1373494-A2 | SUCCINIMIDE AND MALEIMIDE DERIVATIVES AND THEIR USE AS TOPOISOMERASE II CATALYTIC INHIBITORS | Topo Target A/S (DK) | 2004-01-02 | — | — | EP | disclosed |
| US-20030195238-A1 | Drugs such as 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5 -dione inhibitors of glycogen synthase kinase-3 (GSK-3), for prophylaxis of neurodegenerative disorders, cancer, hyperplasia, psoriasis, arteriosclerosis or restinosis | UNIVERSIDAD AUTONOMA DE MADRID (UAM) (ES) | 2003-10-16 | — | — | US | disclosed |
| US-6627364-B2 | Contains (A) a colorant, (B) a binder resin and (C) a solvent having a boiling point of 245 degrees C. or more at normal pressure. | SEIKO EPSON CORPORATION (JP) | 2003-09-30 | — | — | US | disclosed |
| US-20030032625-A1 | Succinimide and maleimide derivatives and their use as topoisomerase II catalytic inhibitors | TOPO TARGET APS (DK) | 2003-02-13 | — | — | US | disclosed |
| WO-2002078679-A2 | SUCCINIMIDE AND MALEIMIDE DERIVATIVES AND THEIR USE AS TOPOISOMERASE II CATALYTIC INHIBITORS | TOPO TARGET APS (DK) | 2002-10-10 | — | — | WO | disclosed |
| US-20020128351-A1 | Ink jet color filter resin composition, color filter and color filter production process | SEIKO EPSON CORPORATION (JP) | 2002-09-12 | — | — | US | disclosed |
| EP-1048700-A1 | Ink jet color filter resin composition, color filter production process | SEIKO EPSON CORPORATION (JP) | 2000-11-02 | — | — | EP | disclosed |
| CN-1009006-B | Thermosetting resin composition, and prepreg and laminated sheet material produced from the same | HITACHI LTD (JP) | 1990-08-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032625-A1 | Succinimide and maleimide derivatives and their use as topoisomerase II catalytic inhibitors | TOP2A, TOP2B, TOP1 | GSK3A 2190/4885GSK3B 1861/4885CMA1 2526/4885 |
| US-20240182467-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, ARAF | GSK3A 657/4885GSK3B 596/4885CMA1 3363/4885 |
| US-12180186-B2 | Quaternary indazole glucocorticoid receptor antagonists | NR3C1, NR3C2, MC2R | GSK3A 1229/4885GSK3B 1023/4885CMA1 3498/4885 |
| US-20030195238-A1 | Drugs such as 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5 -dione inhibitors of glycogen synthase kinase-3 (GSK-3), for prophylaxis of neurodegenerative disorders, cancer, hyperplasia, psoriasis, arteriosclerosis or restinosis | GSK3B, GSK3A, GSKIP | GSK3A 2/4885GSK3B 1/4885CMA1 3281/4885 |
| US-20250214971-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, MC2R | GSK3A 1229/4885GSK3B 1023/4885CMA1 3498/4885 |
| US-20050014803-A1 | Enzyme inhibitors | GSK3B, GSK3A, IDE | GSK3A 2/4885GSK3B 1/4885CMA1 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.